|Table of Contents|

Advances in research on maintenance therapy of metastatic colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
361-364
Research Field:
Publishing date:

Info

Title:
Advances in research on maintenance therapy of metastatic colorectal cancer
Author(s):
MA Hongbo1; ZHOU Qi1; ZHANG Xianquan2
1.Department of Oncology,the Fuling Center Hospital of Chongqing City,Chongqing 408000,China;2.the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China.
Keywords:
metastatic colorectal cancer; maintenance therapy; survival benefit
PACS:
R735.3＋5；R735.3＋7
DOI:
10.3969/j.issn.1672-4992.2021.02.041
Abstract:
Colorectal cancer (CRC) remains one of the most common common malignancy in the world.The introduction of the therapeutic agents such as oxaliplatin,5-fluoropyrimidines (5-FU),irinotecan,and vascular endothelial growth factor antibody and epidermal growth factor receptor (EGFR) inhibitors have significantly improved survival of patients with metastatic colorectal cancer (mCRC) in recent years.Maintenance therapy strategy is the strategy aimed to improve quality of life and survival with low toxicity drugs maintained after induction treatment.Therefore,some clinical studies have evaluated the efficacy and safety of the above-mentioned drugs after the first-line treatment benefit of patients with metastatic colorectal cancer.This article will review the clinical studies of mCRC maintenance treatment regimens so that we can get a more comprehensive view of the advances in the maintenance therapy of mCRC.

References:

［1］ BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
[2] MILLER KD,NOGUEIRA L,MARIOTTO AB,et al.Cancer treatment and survivorship statistics,2019［J］.CA Cancer J Clin,2019,69(5):363-385.
[3] CREMOLINI C,MARMORINO F,LOUPAKIS F,et al.TRIBE-2:a phase III,randomized,open-label,strategy trial in unresectable metastatic colorectal cancer patients by the GONO group［J］.BMC Cancer,2017,17(1):408.
[4] COLUCCI G,GEBBIA V,PAOLETTI G,et al.Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer:A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale［J］.J Clin Oncol,2005,23(22):4866-4875.
[5] TOMITA N,KUNIEDA K,MAEDA A,et al.Phase III randomised trial comparing 6 vs.12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer:Final results of the JFMC37-0801 study［J］.Br J Cancer，2019，120(7):689-696.
[6] YAMADA Y,DENDA T,GAMOH M,et al.S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE):A randomized,open-label,phase III,noninferiority trial［J］.Ann Oncol，2018，29(3):624-631.
[7] MODEST DP,FISCHER VON WEIKERSTHAL L,DECKER T,et al.Sequential versus combination therapy of metastatic colorectal cancer using fluoropyrimidines,irinotecan,and bevacizumab:A randomized,controlled study-XELAVIRI (AIO KRK0110)［J］.J Clin Oncol，2019，37(1):22-32.
[8] SALTZ LB,CLARKE S,DAZ-RUBIO E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase III study［J］.J Clin Oncol，2008，26(12):2013-2019.
[9] MURO K,ITABASHI M,HASHIDA H,et al.Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer:CORAL trial［J］.Jpn J Clin Oncol，2019，49(4):339-346.
[10] KAVEH S,EBRAHIMI P,REZAPOUR A,et al.Bevacizumab and erlotinib versus bevacizumab for colorectal cancer treatment:systematic review and meta-analysis［J］.Int J Clin Pharm，2019，41(1):30-41.
[11] FAKIH MG.Metastatic colorectal cancer:Current state and future directions［J］.J Clin Oncol，2015，33(16):1809-1824.
[12] MA H,WU X,TAO M,et al.Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer:A meta-analysis［J］.Medicine (Baltimore)，2019，98(50):e18227.
[13] TOURNIGAND C,CERVANTES A,FIGER A,et al.OPTIMOX1:A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study［J］.J Clin Oncol，2006，24(3):394-400.
[14] CHIBAUDEL B,MAINDRAULT-GOEBEL F,LIEDO G,et al.Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study［J］.J Clin Oncol，2009，27(34):5727-5733.
[15] WADDELL T,GOLLINS S,SOE W,et al.Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer:XelQuali study［J］.Cancer Chemother Pharmacol，2011，67(5):1111-1117.
[16] LUO HY,LI YH,WANG W,et al.Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer:randomized clinical trial of efficacy and safety［J］.Ann Oncol，2016，27(6):1074-1081.
[17] NAKAYAMA G,KODERA Y,YOKOYAMA H,et al.Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer:CCOG-0704 study［J］.Int J Clin Oncol，2011，16(5):506-511.
[18] HURWITZ H,FEHRENBACHER L,NOVOTNY W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer［J］.N Engl J Med，2004，350(23):2335-2342.
[19] DI BARTOLOMEO M,CIARLO A,BERTOLINI A,et al.Capecitabine,oxaliplatin and irinotecan in combination,with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer.An Italian Trials of Medical Oncology phase II study［J］.Eur J Cancer，2015，51(4):473-481.
[20] DAZ-RUBIO E,GMEZ-ESPAA A,MASSUT B,et al.First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer:the phase III MACRO TTD study［J］.Oncologist，2012，17(1):15-25.
[21] KOEBERLE D,BETTICHER DC,VON MOOS R,et al.Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer:a randomized phase III non-inferiority trial (SAKK 41/06)［J］.Ann Oncol，2015，26(4):709-714.
[22] APARICIO T,GHIRINGHELLI F,BOIGE V,et al.Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer:A randomized phase III trial (PRODIGE 9)［J］.J Clin Oncol，2018，36(7):674-681.
[23] HEGEWISCH-BECKER S,GRAEVEN U,LERCHENMLLER CA,et al.Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207):a randomised,non-inferiority,open-label,phase 3 trial［J］.Lancet Oncol，2015，16(13):1355-1369.
[24] SEEBER A,GUNSILIUS E,GASTL G,et al.Anti-angiogenics:Their value in colorectal cancer therapy［J］.Oncol Res Treat，2018，41(4):188-193.
[25] CHIBAUDEL B,BACHET JB,ANDRT,et al.Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first?line therapy for metastatic colorectal cancer:GERCOR VELVET phase II study［J］.Int J Oncol，2019，54(4):1433-1445.
[26] CREMOLINI C,ANTONIOTTI C,LONARDI S,et al.Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer:A randomized phase 2 clinical trial［J］.JAMA Oncol，2018，4(4):529-536.
[27] ARANDA E,GARCA-AIFONSO P,BENAVIDES M,et al.First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer:Phase II randomised MACRO2 TTD study［J］.Eur J Cancer，2018，101:263-272.
[28] PIETRANTONIO F,MORANO F,CORALLO S,et al.Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer:A phase 2 randomized clinical trial［J］.JAMA Oncol，2019,5(9):1268-1275.
[29] MUNEMOTO Y,NAKAMURA M,TAKAHASHI M,et al.SAPPHIRE:a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer［J］.Eur J Cancer，2019，119:158-167.
[30] TOURNIGAND C,CHIBAUDEL B,SAMSON B,et al.Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3):a randomised,open-label,phase 3 trial［J］.The Lancet Oncology,2015,16(15):1493-1505.
[31] SIMKENS LH,VAN TINTEREN H,MAY A,et al.Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3):a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group［J］.Lancet,2015,385(9980):1843-1852.

Memo

Memo:
-
Last Update: 1900-01-01